Eli Lilly & Company Acquires CrossBridge Bio

Eli Lilly to Acquire Merida Biosciences

August 31, 2026

Biotechnology

Eli Lilly and Company has agreed to acquire Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and contingent milestone payments. The acquisition is intended to expand Lilly’s precision immunology platform for selectively targeting disease-causing antibodies across autoimmune and allergic conditions, including Graves’ disease and thyroid eye disease.

Gilead Sciences to Acquire Tubulis (Up to $5.0B) to Expand ADC Oncology Pipeline

April 7, 2026

Biotechnology

Gilead Sciences entered into a definitive agreement to acquire Tubulis, a Munich-based clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), for $3.15 billion upfront in cash plus up to $1.85 billion in contingent milestone payments. Following completion, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation.

Eli Lilly and Company to Acquire Mablink Bioscience

October 18, 2023

Biotechnology

Mablink Bioscience, a pre-clinical biotechnology company developing antibody-drug conjugates (ADCs) with its PSARLink technology, has entered an agreement to be acquired by Eli Lilly and Company. The acquisition is positioned to expand Mablink’s ADC pipeline and leverage PSARLink to develop additional drug conjugates, subject to French Ministry of the Economy approval.

Lonza Group AG Acquires Synaffix B.V.

June 1, 2023

Biotechnology

Lonza Group AG has acquired Synaffix B.V., a Netherlands-based biotech company that commercialises a clinical-stage antibody-drug conjugate (ADC) technology platform. The deal brings Synaffix's ADC bioconjugation technology into Lonza's integrated ADC development and manufacturing offering to accelerate discovery, development, scale-up and commercialization of ADCs.

Scipher Medicine Acquires CrossBridge to Add Real-time Patient Data and Analytics Platform

January 10, 2023

Data & Analytics

Scipher Medicine has acquired Philadelphia-based data, analytics, and software company CrossBridge to bolster its data management and analytics capabilities. The acquisition (closed; terms not disclosed) adds CrossBridge's SaaS value-based care platform to enable real-time mapping of patient molecular, clinical and claims data and to support Scipher's precision immunology offerings such as the PrismRA test.

Sterling Pharma Solutions Acquires ADC Biotechnology

April 7, 2021

Biotechnology

Sterling Pharma Solutions, a GHO Capital portfolio CDMO, has acquired ADC Biotechnology (ADC Bio), a Deeside-based bioconjugation and ADC development services business. The deal adds ADC capabilities and a Deeside facility to Sterling’s international network and includes multi-million pound investment to grow bioconjugation, analytical and cGMP ADC manufacturing capabilities.